Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

s in the STARTVerso™ program (STARTVerso™3) are treatment-experienced, meaning they had attempted previous HCV treatment but did not achieve viral cure
  • 40% of patients in STARTVerso™3 (treatment-experienced patients) have advanced liver disease (>/=F3 fibrosis)
  • 59% of patients in STARTVerso™1&2 (treatment-naive patients) have a non-CC IL28B genotype; in previous studies, these patients have been less likely to achieve viral cure
  • "These pivotal data from STARTVerso™ are important for Boehringer Ingelheim's HCV portfolio as they support the filing of a New Drug Application for faldaprevir with the Food and Drug Administration," said Peter Piliero, M.D., vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "These results take us a step closer towards our goal of making faldaprevir available for patients who urgently need HCV treatment."

    In the STARTVerso™ clinical trial program, adverse events (AEs) most commonly included nausea, fatigue, diarrhea, headache, anemia, weakness, rash and jaundice due to transient bilirubin elevation (unconjugated hyperbilirubinemia). In STARTVerso™1&2, anemia occurred in 14%, 13%, and 14% of patients taking 120mg and 240mg faldaprevir regimens or PegIFN/RBV alone, respectively. Hyperbilirubinemia occurred in 12% (120mg), 46% (240mg) and less than 1% (PegIFN/RBV) of patients, and was transient. ALT elevations in the faldaprevir arms were similar to placebo, and occurred in 2% (120mg), 2% (240mg) and 3% (PegIFN/RBV) of patients. Gastrointestinal side effects occurred in 11% (120mg), 18% (240mg) and 7% (PegIFN/RBV) of patients. Rash occurred in 7% (120mg), 10% (240mg) and 4% (PegIFN/RBV) of patients. There was no occurrence of photosensitivity in the faldaprevir 120mg arm, and a 1% occurrence in the 240mg arm. Bilirubin associated AEs occurred in 3% (120mg), 9% (240mg) and
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
    3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
    5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
    6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
    7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
    8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
    9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
    10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
    11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... FRANCISCO, Calif. , Aug. 27, 2015 /PRNewswire/ ... therapeutics for the treatment of cancer, today announced ... member of the company,s Board of Directors, has ... led immuno-oncology at Eli Lilly and AstraZeneca, and ... first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb ...
    (Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
    (Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... PhD, Chief Executive Officer, will present a corporate overview and ... in New York City . , ... at 11:30 am ET at the Millennium Broadway Hotel. ... 3:00 pm ET at the St. Regis Hotel. ...
    Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3SciClone To Present At Two Investor Conferences On September 10, 2015 2
    ... , NANJING , China ... SCR ), a leading manufacturer and supplier of ... (also known as Endu) in China , announced today ... conference in Beijing ,dedicated to this study. The New ...
    ... March 18 Jeffrey B. Kindler , ... chairman of the Pharmaceutical Research and Manufacturers of America ... elected were sanofi-aventis Chief Executive Officer Christopher Viehbacher ... and John C. Lechleiter , Ph.D., Chairman, President ...
    Cached Medicine Technology:Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 2Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 3Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 4Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8
    (Date:8/27/2015)... ... 27, 2015 , ... About 10 percent of mothers experienced ... Coast, killing more than 1,800 people, displacing hundreds of thousands and causing widespread ... study. , While most people don’t develop persistent depression after a major disaster ...
    (Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
    (Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... In addition ... Alvernia University now offers a third doctoral program at its main campus in Reading: ... a terminal degree program designed to prepare advanced practice nurses for the highest level ...
    (Date:8/27/2015)... London, UK (PRWEB) , ... ... ... Ltd and Black Swan Analysis signed a partnership agreement for quality market ... sell research reports elaborated by Black Swan Analysis. , Commenting on the ...
    (Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
    Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
    ... reduces the risk of heart disease. But almost everyone feels ... recent study shows that skinny people are also prone to ... factors in the genesis of various heart ailments. ,Dr. ... who headed the study, says that heart disease does not ...
    ... is playing havoc with the economies of,developed countries like ... of vaccinating the animals for the past three decades. ... regular basis is the best,means of preventing the spread ... joint,director of the Bangalore-based Indian Veterinary Research Institute (under,ICAR), ...
    ... research backed by the British government says that smoking will ... to come, surpassing the threat of even HIV. The British ... smoking will kill more people than any other disease in ... of Development Studies in Sussex, United Kingdom, says smoking and ...
    ... States of America has zeroed in on the culprit behind ... isolated which is said to be the cause for girls ... most widely held explanation for this is growing childhood obesity, ... were keen on the role of estrogen, a female hormone, ...
    ... are paranoid about heart disease. One survey said that of ... heart disease. Whenever people get to read something on heart ... worrying at times over trivial problems based on the assumption ... conducted in Austria says that chronic infections can predispose to ...
    ... A study conducted by Dr. Michael Brent, an associate ... St. Louis, gives us an insight into the way ... age.,These findings were presented at the annual meeting of ... San Francisco.,For years the ability of children to pick ...
    Cached Medicine News:Health News:India takes on foot-and-mouth disease by vaccinating animals 2
    Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
    Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
    ... 3 system consists of the Model 7432 ... MemoryMod Software Cartridge. , ,Enterra™ Therapy ... nausea and vomiting associated with gastroparesis when ... relief of symptons for diabetic or idiopathic ...
    ... Intramuscular Lead is a unipolar lead intended for ... has a ski needle design for easier use ... a fixed electrode length of 1 cm. The ... is available in 35 cm length. Two leads ...
    Medicine Products: